About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
XL t(14;18) IGH/BCL2 DF
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl (10 Tests)
XL t(14;18) IGH/BCL2 DF consists of a green-labeled probe hybridizing to the IGH gene region at 14q32.3 and an orange-labeled probe hybridizing to the BCL2 gene region at 18q21.3.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
Rearrangements of the immunoglobulin heavy chain (IGH) gene locus are present in about 50% of all non-Hodgkin lymphomas (NHL) including follicular lymphomas (FL) and diffuse large B-cell lymphomas (DLBCL). FL is the most common indolent form of NHL and accounts for about 20-30% of all lymphoid tumors. The reciprocal translocation t(14;18)(q32;q21) can be detected in about 85% of FL patients and in up to 35% of patients with DLBCL. t(14;18) juxtaposes BCL2 to transcriptional enhancers in the IGH locus and results in overexpression of the BCL-2 protein in neoplastic follicles. BCL2 is involved in the regulation of programmed cell death and shows anti-apoptotic characteristics. Overexpression of BCL2 leads to a high number of B-cells having a prolonged lifespan in germinal centers. This increases the chance to acquire additional chromosomal alterations required for the neoplastic transformation of B-cells.
- Non-Hodgkin Lymphomas (NHL)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.
- Bernicot et al (2005) Anticancer Res 25:3179-3182
- Ott and Rosenwald (2008) Haemotologica 93:1773-1776
- Freedman (2014) Am J Hematol 89:429-436